DE69331825D1 - Zusammensetzungen und methoden der inhibition der beta-proteinfunktion - Google Patents

Zusammensetzungen und methoden der inhibition der beta-proteinfunktion

Info

Publication number
DE69331825D1
DE69331825D1 DE69331825T DE69331825T DE69331825D1 DE 69331825 D1 DE69331825 D1 DE 69331825D1 DE 69331825 T DE69331825 T DE 69331825T DE 69331825 T DE69331825 T DE 69331825T DE 69331825 D1 DE69331825 D1 DE 69331825D1
Authority
DE
Germany
Prior art keywords
inhibition
compositions
methods
protein function
beta protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69331825T
Other languages
English (en)
Other versions
DE69331825T2 (de
Inventor
Huntington Potter
Usamah Kayyali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of DE69331825D1 publication Critical patent/DE69331825D1/de
Publication of DE69331825T2 publication Critical patent/DE69331825T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
DE69331825T 1992-01-13 1993-01-13 Zusammensetzungen und methoden der inhibition der beta-proteinfunktion Expired - Fee Related DE69331825T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/819,361 US5338663A (en) 1990-08-24 1992-01-13 Method of identifying inhibitors of β-protein esterase activity
PCT/US1993/000325 WO1993015112A2 (en) 1992-01-13 1993-01-13 COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FUNCTION

Publications (2)

Publication Number Publication Date
DE69331825D1 true DE69331825D1 (de) 2002-05-23
DE69331825T2 DE69331825T2 (de) 2002-11-28

Family

ID=25227943

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69331825T Expired - Fee Related DE69331825T2 (de) 1992-01-13 1993-01-13 Zusammensetzungen und methoden der inhibition der beta-proteinfunktion

Country Status (5)

Country Link
US (1) US5338663A (de)
EP (1) EP0623146B1 (de)
JP (1) JPH07509447A (de)
DE (1) DE69331825T2 (de)
WO (1) WO1993015112A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5506097A (en) * 1990-08-24 1996-04-09 President And Fellows Of Harvard College Method for inhibiting β-protein enzymatic activity
US6180771B1 (en) * 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
JP2968048B2 (ja) * 1995-05-12 1999-10-25 シェーリング コーポレイション 表面プラズモン共鳴に基づく酵素アッセイ
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6017723A (en) * 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
NZ514414A (en) * 1999-03-04 2004-02-27 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation comprising D-amino acids
EP1328261A2 (de) * 2000-04-12 2003-07-23 Minerva Biotechnologies Corporation Behandlung von neurodegenerativen krankheiten
ZA200702869B (en) * 2004-10-06 2008-07-30 Mori Hiroshi Mutated amyloid protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273866A (en) * 1979-02-05 1981-06-16 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates and methods for use
US4303592A (en) * 1980-01-09 1981-12-01 Center For Blood Research, Inc. Amidinophenylmethylsulfonylfluoride
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
US5187153A (en) * 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5079336A (en) * 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
WO1991013904A1 (en) * 1990-03-05 1991-09-19 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
AU643835B2 (en) * 1990-08-17 1993-11-25 Boston University Proteases causing abnormal degradation of amyloid beta-protein precursor
JPH06500560A (ja) * 1990-08-24 1994-01-20 プレジデント アンド フェローズ オブ ハーバード カレッジ α―アンチキモトリプシン―β―タンパク質複合体形成妨害方法およびその方法に使用する合成ペプチド

Also Published As

Publication number Publication date
EP0623146A1 (de) 1994-11-09
JPH07509447A (ja) 1995-10-19
EP0623146B1 (de) 2002-04-17
WO1993015112A3 (en) 1993-09-02
WO1993015112A2 (en) 1993-08-05
DE69331825T2 (de) 2002-11-28
US5338663A (en) 1994-08-16

Similar Documents

Publication Publication Date Title
FI944885A (fi) Tölkin perusosa
FI935223A (fi) Rake-mottagare med selektiv kombinering av straolar
DE69325158D1 (de) Photokromische Zusammensetzung
FI951197A (fi) Mikrobisidiset koostumukset ja menetelmät
MX174001B (es) Composiciones cementicias y metodo
FI930376A0 (fi) Tillslutningsanordning av gaengtyp med saekringsorgan
FI89097C (fi) Matningsbomanordning vid bergsborr
DE69331825D1 (de) Zusammensetzungen und methoden der inhibition der beta-proteinfunktion
FI931408A (fi) Anordning foer fraesning av amorfiska staolremsor
FI934519A0 (fi) Foerfarande foer finfoerdelning av inmatat material vid en kvackningsprocess med flytbaeddskatalysator
NO930574L (no) Fremgangsmaate for fremstilling av desfluran
DE69323965D1 (de) Stabilisierte Polyester-Polycarbonat Zusammensetzungen
BR8905444A (pt) Composicoes e aplicacao
NO940190D0 (no) Anvendelse av x-ketoglutarat
DE3586256D1 (de) Polyglycidamide und ueberzugzusammensetzungen.
NO930470D0 (no) Framgangsmaate for framstilling av ferrosilisum-legering
DE69217904D1 (de) Zusammensetzung
FI910207A (fi) Fungisidisia vaikuttavien aineiden yhdistelmiä
DK0599461T3 (da) Hærdelige sammensætninger
KR930021041U (ko) 식기세척기의 상판과 케이스의 결합수단
KR930026760U (ko) Tvcr의 개선된 구성
LV10073A (lv) Skidinataju absolutizesanas panemiens
FI921063A (fi) Foerfarande foer reparering av en stolpes roetskadade nebre aenda i en byggnad med traestomme
FI930088A0 (fi) Urinsamlare foer underlaettande av provtagning fraon barn
LV10486A (lv) Ingredientu kompozicija aperitivam

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Free format text: G. KOCH UND KOLLEGEN, 80339 MUENCHEN

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee